Genmab A/S Reaches Third Milestone in H. Lundbeck A/S Collaboration

Copenhagen, Denmark; December 13, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the third pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment (approximately DKK 7.5 million). Under the collaboration with Lundbeck, Genmab creates novel human antibodies to three central nervous system (CNS) targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities.